Hospital admission rates and related outcomes among adult Aboriginal australians with bronchiectasis – a ten-year retrospective cohort study

Table 1 Demographic and clinical information of patients split by whether had a hospitalisation during the study period

Clinical parameters	No admissions (n = 61)	Admissions (n = 396)	RW p-value
Age	52.75 (47.5, 64.56)	56.06 (48.67, 65.3)	0.882
Female	40 (65.6%)	214 (54%)	0.882
Remote / very remote	59 (96.7%)	364 (91.9%)	0.941
BMI (kg/m²) (n = 17 & 152)	26.53 (20.2, 31.6)	22.95 (18.97, 26.25)	0.588
Never smoker (n = 16 & 134)	2 (12.5%)	20 (14.9%)	1.000
Former smoker (n = 16 & 134)	8 (50%)	56 (41.8%)	1.000
Current Smoker (n = 16 & 134)	6 (37.5%)	58 (43.3%)	1.000
FVC (% predicted) (n = 17 & 152)	63 (56, 67)	49 (38.5, 63)	0.118
FEV₁ (% predicted) (n = 17 & 152)	55 (51, 63)	35.95 (27, 48.5)	0.029
FEV₁/FVC (n = 17 & 152)	0.77 (0.65, 0.82)	0.65 (0.48, 0.76)	0.235
Respiratory co-morbidities
COPD	29 (47.5%)	349 (88.1%)	0.029
Asthma	11 (18%)	106 (26.8%)	0.912
Lung cancer	3 (4.9%)	15 (3.8%)	1.000
ILD	0 (0%)	3 (0.8%)	-
Other medical co-morbidities
Hypertension	37 (60.7%)	250 (63.1%)	1.000
Type 2 diabetes	28 (45.9%)	194 (49%)	1.000
Chronic kidney disease	27 (44.3%)	157 (39.6%)	1.000
CAD	17 (27.9%)	142 (35.9%)	0.971
HF	4 (6.6%)	35 (8.8%)	1.000
Bronchiectasis chest CT location
LLL	43 (70.5%)	293 (74%)	1.000
RLL	35 (57.4%)	249 (62.9%)	1.000
RML	30 (49.2%)	164 (41.4%)	0.971
RUL	18 (29.5%)	108 (27.3%)	1.000
Lingula	18 (29.5%)	110 (27.8%)	1.000
LUL	11 (18%)	89 (22.5%)	1.000
Bilateral	39 (63.9%)	257 (64.9%)	1.000
Medications
SABA	28 (45.9%)	256 (64.6%)	0.118
SAMA	0 (0%)	32 (8.1%)	-
LABA	21 (34.4%)	256 (64.6%)	0.029
LAMA	14 (23%)	197 (49.7%)	0.059
ICS	18 (29.5%)	232 (58.6%)	0.029

p-values derived from quantile regression (continuous parameters) or logistic regression (categorical parameters), with additional adjustment for multiple comparisons via Romano-Wolf correction
BMI, smoking status and lung function parameters were only available in a subset of patients, with the number available lifted in the leftmost column
Abbreviations: BMI Body mass index, FVC Forced vital capacity, FEV₁ Forced expiratory volume in one second, COPD Chronic obstructive pulmonary disease, ILD Interstitial lung disease, HF Heart failure, CAD Coronary artery disease, LLL Left lower lobe, RLL Right lower lobe, RML Right middle lobe, RUL Right upper lobe, LUL Left upper lobe, RW-p Romano-Wolff p-value, SABA Short acting beta agonist, LABA long acting beta agonist, SAMA short acting muscarinic agent, LAMA long acting muscarinic agent, ICS inhaled corticosteroids.

ISSN: 1471-2466